Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HPGD | P15428 | 2/20 | 0.42 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.42 |
| ▸ | SMN1; SMN2 | Q16637 | 3/20 | 0.42 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.42 |
| ▸ | NPC1 | O15118 | 2/20 | 0.42 |
| ▸ | MEN1 | O00255 | 2/20 | 0.42 |
| ▸ | POLB | P06746 | 1/20 | 0.42 |
| ▸ | RAB9A | P51151 | 1/20 | 0.42 |
| ▸ | FFAR1 | O14842 | 1/20 | 0.42 |
| ▸ | FFAR4 | Q5NUL3 | 1/20 | 0.42 |
| ▸ | GAA | P10253 | 2/20 | 0.41 |
| ▸ | MAPK8 | P45983 | 1/20 | 0.40 |
| ▸ | P2RX7 | Q99572 | 2/20 | 0.40 |
| ▸ | HTT | P42858 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL12201835 | 0.86 | SMN1; SMN2 (0.42) | HPGDALDH1A1SMN1; SMN2KMT2ANPC1 | |
| SCHEMBL5298485 | 0.85 | NPC1 (0.54) | HPGDALDH1A1SMN1; SMN2KMT2ANPC1 | |
| SCHEMBL9890752 | 0.84 | SMN1; SMN2 (0.42) | ALDH1A1SMN1; SMN2KMT2AMEN1RAB9A | |
| SCHEMBL9890755 | 0.84 | GRIN1 (0.42) | ALDH1A1SMN1; SMN2KMT2ARAB9AGAA | |
| SCHEMBL9890756 | 0.84 | SUCNR1 (0.46) | KMT2ANPC1MEN1POLBRAB9A | |
| SCHEMBL9890712 | 0.83 | SMN1; SMN2 (0.47) | HPGDALDH1A1SMN1; SMN2KMT2ANPC1 | |
| SCHEMBL8568769 | 0.82 | P2RX7 (0.49) | HPGDALDH1A1SMN1; SMN2KMT2ANPC1 | |
| SCHEMBL9890718 | 0.81 | KMT2A (0.49) | ALDH1A1SMN1; SMN2KMT2ANPC1MEN1 | |
| SCHEMBL2395314 | 0.81 | RAB9A (0.49) | HPGDALDH1A1SMN1; SMN2KMT2AMEN1 | |
| SCHEMBL2397419 | 0.81 | KMT2A (0.51) | HPGDALDH1A1KMT2ARAB9AFFAR1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20120142771-A1 | BIPHENYLACETAMIDE DERIVATIVE | DAINIPPON SUMITOMO PHARMA CO., LTD. (JP) | 2012-06-07 | — | — | US | disclosed |
| US-20110224304-A1 | BIPHENYLACETAMIDE DERIVATIVE | DAINIPPON SUMITOMO PHARMA CO., LTD. (JP) | 2011-09-15 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120142771-A1 | BIPHENYLACETAMIDE DERIVATIVE | HRH3, KCNH3, BRPF3 | HPGD 3524/4885ALDH1A1 576/4885SMN1; SMN2 2980/4885 |
| US-20110224304-A1 | BIPHENYLACETAMIDE DERIVATIVE | HRH3, KCNH3, BRPF3 | HPGD 3524/4885ALDH1A1 576/4885SMN1; SMN2 2980/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.